Upload
others
View
5
Download
0
Embed Size (px)
Citation preview
MASTERCLASS: BRACHYTHERAPY in PARTIAL BREAST IRRADIATION
Euro-Asian Breast Brachytherapy School
October 8-9th, 2015
Singapore
BRACHYTHERAPY IN PARTIAL BREAST IRRADIATION
Fractionation concepts, radiobiologic considerations
Dr. José Luis Guinot
Foundation Instituto Valenciano de Oncologia (I.V.O.) Spain.
- A 1cc tumour has 109 clonogenic cells,one billion cells.
- The objective of radiation is to kill allresidual cells in the tumour bed afterbreast surgery, therefore the number ofclonogenic cells is low.
- Partial breast irradiation is treating bothresidual cells and normal breast tissue,not the tumour itself.
The sensitivity of a tissue or tumour toradiation is measured by the a/b value
- a/b is very similar for breast tumorsand breast tissue.
- Hypofractionated treatments are moreadequate for slow growing breast tumors
- There is no standard protocol for APBI,but shorter schedules should be better…
The goal with APBI
Presence of tumoral cells at a
distance from the primary tumour
What do we need to treat with APBI?
In APBI we are treating residual cells, not the tumour. Margin should be free.
We cannot compare breast brachytherapy with other locations as cervix.
Veronesi U. Radiotherapy after breast-conserving surgery in small breast carci-
noma. Long-term results ps a randomized trial. Ann Oncol 12; 2001:997-1003.
What do we control with radiation?
•We treat 100% BCS cases
•RT control ¼ cases
•RT failures due to unsufficient dose
(total dose)•Some failures due to missing PTV
(technique)
What can we learn about radiobiology?
1.0
0.1
0.01
0.001
Accumulation ofsub-lethal
damage
single lethal hits
n
dose
Surviving Fraction depends on the dose of radiation
Puck and Marcus, J.E.M.103, 563, 1956
First in vitro mammalian survival curve
Two component model:
Eukaryotic survival curves are
exponential but have a shoulder
From William McBride. Dept. Radiation Oncology.
David Geffen School Medicine. UCLA, Los Angeles, Ca
Cell kill is the result of single lethal hits
plus accumulated damage from 2
independent sublethal events
E = aD + bD2
For a fractionated regimen
E= nd(a + bd) = D (a + bd)
Where d = dose per fraction and D = total dose
a/b is dose at which death due tosingle lethal lesions = death due toaccumulation of sublethal lesions
aD = bD2
S.F. = e-aD
Single lethal hits
S.F. = e-(aD+bD2)
Single lethal hits plus
accumulated damage
Survivinigfraction.
1.0
0.1
0.01
0.001
DOSE Gy
a/b in Gy
aD
bD2
Linear Quadratic Model
From William McBride. Dept. Radiation Oncology.
David Geffen School Medicine. UCLA, Los Angeles, Ca
From Pravin U.
Dugel, Jeffrey
Nau, Ram Palanki
242016128400
.01
.1
1
Dose (Gy)
S.F.
Single dose
limiting slope/
low dose rate
3 fractions
5 fractions
Multi-fraction survival curves can be considered linear if sublethal damage is repaired between fractions
Multi-fraction survival curves
From William McBride. Dept. Radiation Oncology.
David Geffen School Medicine. UCLA, Los Angeles, Ca
Response to Fractionation Varies With Tissue
Modified from William McBride. Dept. Radiation Oncology.
David Geffen School Medicine. UCLA, Los Angeles, Ca
a/b is high (>6Gy) when survival
curve is almost exponential and low
(1-4Gy) when shoulder is wide
Fractionation has small influence
on acute effects and tumours. But
it spares late responding tissues
Response to Fractionation Varies With Tissue (a/b)
The advantage of using more fractions with a/b 10 is that when all
clonogenic cells are killed, enough normal cells remain to recover tissues
To kill all clonogenic cells with a/b low, fewer fractions are better
Redistribution
Repair
Repopulation
700R 1500R
What is happening between fractions?4Rs of dose fractionation
• Assessed by varying the
time between 2 or more
doses of radiation
• With HDR BT six hours
between fractions allow the
recovery of normal tissues.
• Repopulation requires
longer times: Avoid
weekends
Reoxygenation
Modified from William McBride. Dept. Radiation Oncology.
David Geffen School Medicine UCLA, Los Angeles, Ca
Response with different dose rates.
• With HDR brachytherapy, doses are higher in a short time , and SF is lower
Response with different dose rates.
• With LDR brachytherapy, surviving fraction is lower with higher dose rates
• Both a and b vary with the cell cycle. At high doses, S phase and hypoxic cells become more important.
• The a/b ratio varies depending upon whether a cell is proliferative or quiescent (breast?)
• The LQ model best describes data in the range of 1 - 6Gy and should not be used outside this range
(what to do with HDR in few fx.?)
Problems with a/b
The a/b value quantifies the sensitivity of a tissue/tumor to fractionated radiation. But…
Dose
oxic
hypoxicS.F
Modified from William McBride. Dept. Radiation Oncology.
David Geffen School Medicine UCLA, Los Angeles, Ca
What are a/b ratios for breast cancers?
a/b ratios may be moderately low
– Owen JR et al. Lancet Oncol 2006; 7: 467-471,
– Dewar et al. JCO 2007 , ASCO Proceedings Part I. Vol 25, No. 18S: LBA518
• UK START Trial
– 50Gy (2x25), compared with
39Gy (3x13) 41.6Gy (3.2x13) 40Gy (2.67 x15)
• Breast Cancer a/b = 4.0Gy (1.0-7.8)
• Breast appearance a/b = 3.6Gy;
• Breast induration a/b = 3.1Gy
If fractionation sensitivity of a cancer is similar to dose-limiting healthy
tissues, it may be possible to give fewer, larger fractions without
compromising effectiveness or safety
From William McBride. Dept. Radiation Oncology.
David Geffen School Medicine UCLA, Los Angeles, Ca
How to compare different doses?
What total dose (D) to give if the dose/fx (d) is changed
New Old
Dnew (dnew + a/b) = Dold (dold +a/b)
What total dose in 4Gy fractions is equivalent to 50Gy in 2Gy fractions?
for acute responding tissue a/b:10
Dnew (4+10) = 50 (2 + 10) Dnew = 42.8Gy
for late responding tissue a/b:3
Dnew (4+3) = 50 (2 + 3) Dnew = 35.7Gy
for breast tissue a/b:4
Dnew (4+4) = 50 (2 + 4) Dnew = 37.5Gy
Small differences in a/b for late responding tissues can make a big
difference in estimated total dose D
Modified from William McBride. Dept. Radiation
Oncology. David Geffen School Medicine UCLA, Los
Angeles, Ca
Late responding tissues respond badly to increased dose/fraction
When increasing dose/fraction, total dose must be decreased.
Modified from William McBride. Dept. Radiation Oncology.
David Geffen School Medicine UCLA, Los Angeles, Ca
The effect on late responding tissues varies with dose/fx
Looking for a common language
Biologically Effective
Dose (BED) Total dose
RE: Relative
Effectiveness
S.F. = e-E = e-(aD+bD2)
E = nd(a + bd)
E/a = nd (1+d/a/b)
25 x 2Gy = 50 Gy B.E.D. of 60Gy10 75Gy4 83.5Gy3
Dose equivalent to 2Gy EQD2 = Normalized total dose2Gy = BED/RE
for a/b of 10Gy = BED / 1.2
for a/bof 4Gy = BED / 1.5
for a/bof 3Gy = BED / 1.67
Modified from William McBride. Dept. Radiation Oncology.
David Geffen School Medicine UCLA, Los Angeles, Ca
(EQD2) Biologically Effective Dose (BED)
LDR brachytherapy BED values
EBRT and HDR brachytherapy BED values
α / β : 10 7
x
4.3
10
x
3.4
8
x
4
7
x
5.2
8
x
5
10
x
3.8
5
x
6
Rosenstein BS et al, IJROBP 2004;60:1393-1404
α / β : 2
Late effects7
x
4.3
10
x
3.4
8
x
4
7
x
5.2
8
x
5
10
x
3.8
5
x
6
Rosenstein BS et al, IJROBP 2004;60:1393-1404
α / β : 4
Breast
10
x
3.4
7
x
4.3
8
x
4
7
x
5.2
5
x
6
8
x
5
10
x
3.8
Rosenstein BS et al, IJROBP 2004;60:1393-1404
daysTotaldose
BED Gy10
BED Gy2
BED Gy3
BED Gy4
8 x 4Gy 4-5 32 45 96 74.8 64
10x3.4Gy 5 (7) 34 46 92 72.8 63
EQD2
8 x 4Gy 32 37.5 57.5 44.8 42.7
10x3.4Gy 34 38 55 43.6 42
Comparison of BED and EQD2 in standard APBI protocols with brachytherapy
The selected total dose chosen in current schedules is low compared with EBRT
BED and repopulation with EBRT
• The standard schedule is 60 Gy in 2-Gy fractions.
• Assuming tumor parameters α / β= 4 Gy, if repopulation effects are neglected, 60 Gy/30 fractions delivers a tumor BED of 90 Gy4.
• Wyatt et al. have reviewed postoperative repopulation parameters relevant to breast cancer and used a K factor of 0.1 Gy/day.
• A 30-fraction treatment lasts around 39 days, thus the calculated BED is reduced by 39 x 0.1 = 3.9 Gy, that is, the reference tumor BED, corrected for repopulation, is
BED 90 - 3.9 = 86 Gy4.
Khan AJ et al. Ultrashort courses of adjuvant breast radiotherapy. Wave of the future or a
fool’s errand? Cancer 2012;118:1962-70.
Study PatientsTotal dose
Numberfx
Fx size(Gy)
weeksAsumedα/β
START A 223641.6Gy 13 3.2 5 4 Gy
39Gy 13 3.0 5 3 Gy
START B 40Gy 15 2.67 3
Ontario 1234 42.7Gy 16 2.67 3
FAST 91530Gy 5 6.0 5 4Gy
28.5Gy 5 5.7 5 3Gy
FAST forward
4000 prev27Gy 5 5.4 1 3Gy
26Gy 5 5.2 1
Hypofractionated protocols in breast EBRT
Schedules of hypofractionated WBI similar to HDR brachytherapy
are under investigation
Altered fractionations
Rationale of Proposed Fractionation Schemes
• The primary rationale for APBI is the enhanced convenience for patients, which may result in increased access to BCT.
• The fractionation schemes for APBI were devised empirically.
• With the low α / β ratio for breast cancer, the fraction sensitivity of breast cancer can be exploited with higher fraction sizes, resulting in even more compressed treatment times.
• Not to exceed the tolerance of normal tissues.
Khan AJ et al. Ultrashort courses of adjuvant breast radiotherapy. Wave of the future or a
fool’s errand? Cancer 2012;118:1962-70.
HDR APBI over two days
• The William Beaumont Hospital (Michigan)
• 45 patients, phase 1-2 protocol , single-lumen MammoSite RTS applicator.
• 7 Gy x 4 fractions over 2 days ,
• Median age 66 years (48-83), median tumor size 0.6 cm (0.2-2.3 cm) 5% N+, 73% ER +. Median FU 3.7 years (2.4-7).
• Only G 1-2 chronic toxicities were noted: fat necrosis (18%), asymptomatic seromas (42%), 7% rib fractures (n=3)
• 98% good or excellent cosmetic outcome.
• No ipsilateral breast tumor recurrences or regional nodal failures; 2 M+.
• CONCLUSIONS: acceptable chronic toxicity and similar clinical outcomes as standard 5-day fractionation.
Wilkinson JB et al. Four-year results using balloon-based brachytherapy to deliver
accelerated partial breastirradiation with a 2-day dose fractionation schedule.
Brachytherapy. 2012 Mar-Apr;11(2):97-104.
Prospective trial of ultrashort-course APBI using a multi-lumen balloon brachytherapy device
• A prospective phase II trial that sequentially treats 3 cohorts of women (each n = 30) with 3 progressively hypofractionatedschedules.
• Age ≥50 years, unifocal invasive or in situ tumors ≤3.0 cm, negative margins, N -hormone receptors +.
• 30 patients enrolled at the 7 Gy × 4 fractions followed 6 m.
• Median skin dose 84% (40-100), median rib dose 71% (16-119).
• 1 breast infection; 2 symptomatic fat necrosis ; 2 symptomatic seromas.
• CONCLUSION: Short-course APBI is dosimetrically feasible using the Contura MLB and appears to be tolerable in terms of acute toxicities.
• We have opened enrollment to the next schedule of 8.25 Gy x 3
Khan AJ, et al. Dosimetric feasibility and acute toxicity in a prospective trial of ultrashort-course
accelerated partial breast irradiation (APBI) using a multi-lumen balloon brachytherapy device. Ann Surg
Oncol. 2013; 20(4):1295-301
Radiobiological influence of gradient with balloon applicators
• Dale et al calculate a multiplication factor (MF) to multiply theprescribed BED to take account of the dose gradient effect, theradiosensitivity parameters, the fractional dose, and thenumber of fractions.
Dale R, et al. Calculation of integrated biological response in brachytherapy. IJROBP
1997;38:633-642.
• Dose is prescribed 1 cm from the balloon surface. (Diameter 4.5cm, radius 2.25, prescription point 3.25cm)• There is a large dose gradient. The surface dose is 44% higher than the prescription dose.
Khan AJ et al. Ultrashort courses of adjuvant breast radiotherapy. Wave of the future or a
fool’s errand? Cancer 2012;118:1962-70.
α / β : 4
Breast
10
x
3.4
7
x
4.3
8
x
4
7
x
5.2
5
x
6
8
x
5
10
x
3.8
Rosenstein BS et al, IJROBP 2004;60:1393-1404
• Intraoperative HDR technique using a Silastic applicator (Harrison-Anderson-Mick or HAM applicator)
• Single fraction of 20 Gy at 1 cm from the surface of the
applicator.
• This was modified to 18 Gy at the lateral aspects of the applicator, because 5 of the first 18 patients developed significant fibrosis and retraction at the 6-month interval.
• 90 Gy delivered in 2-Gy fractions, (α/β:3) for normal tissue effects.
• the investigators do not report accounting for the steep gradient of inhomogeneity within the prescription volume.
• After the modest dose reduction, fewer complications were noted, although the reported follow-up is short.
Sacchini V, et al. Study of quadrant high-dose intraoperative radiation therapy for early-stage
breast cancer. Br J Surg. 2008;95:1105-1110.
HDR single fraction
SIFEBI
• 16 Gy in one fraction. Age >=70 years, pT1pN0, margins-
• This dose is calculated with α/β for the breast, on the order of 3.4 Gy for late toxicity and 4.6 Gy for local control.
• Applying the linear-quadratic model with α/β = 4, 16 Gy x1 is equivalent to 53 Gy in conventional fractionation.
• BED is between the dose in the protocols IPAS intraoperative electron or X-ray photons of 50 kV (21 Gy in one fraction, 87 Gy EQD2 α/β= 4.6) and the post-operative irradiation of 34-38 Gy in 10 fractions, 5 days (42 Gy EQD2 α/β= 4.6)
• (First results in ESTRO…)
Single Fraction Elderly Breast Irradiation (SiFEBI)
J.M. Hannoun-Levi. Centre Antoine Lacassagne. Nice. France.
Dose
Therapeutic window: To choose the right dose
100%
0%
Wide
therapeutic
window
100%
0%
Narrow
therapeutic
window
Tumor control
Late responding tissue
complications
Complication-free cure
α / β : 4
Breast
Inhomogeneity of HDR brachytherapy
Local relapse 3.9% CosmesisExcellent-good 38%Moderate 55%Bad 7%
HDR: 9.7 Gy (7 – 12 Gy)
LDR: 20 Gy (9.9 - 27 Gy)
Resch A. Long-term results (10 years) of intensive breast conserving therapy including a high-dose and large-volume interstitial brachytherapy boost (LDR/HDR) for T1/T2 breast cancer. Radiother Oncol 2002;63:47-58
410 patients (Viena)
Importance of the prescription: Boost HDR to 10mm
↑25%↑31%
ROIDose(%)
Dose(cGy)
Volume(ccm)
DNRV150/V100
External 100 400 970.31
External 150 600 30
External 100 400 970.5
External 150 600 49
Importance of hot spots on HDR brachytherapy
Prescription is 4Gy but one half of the
volume receives 6Gy
In brachytherapy the dose inside the treated volume is far higher than the prescribed dose
J Contemp Brachyther 2012; 4,1:12-20
The inevitable dose gradient in BT ensures non-uniform dosage within the target volume and this extra-dose has its own biological effect
Importance of gradient on HDR brachytherapy
10 x 3.4 Gy
α/β 10: 13.5 Gy
Single fraction 8 Gy
α/β 4: 17 Gy
α/β 4: 20-25 Gy
Taking into account the dose gradient
Conclusions
CURRENT MODEL OF FRACTIONATION
BREAST CANCER: HYPOFRACTIONATION
α/β4,5
Radiobiological justification: Tumour α/β <10 will response better
to higher doses than standard 2Gy fractionation
α/β10
© Manuel Algara
• The Swedish Insurance Company
• Fractions from 2.5-6Gy
• BED up to 146 EQD2 (6Gy x 13fx).
• >95% had stiff shoulder, paralysis, pain, oedema, atrophy.
• Latency as long as 30years
• CONCLUSION: HFX can cause injuries if the target volume is not
exact or the total dose is not adjusted to a tolerable level as
compared to conventional 2Gy/day fractions.
© Manuel Algara
Smith GI, Xu Y, Buchholz TA, et al.
JAMA 2012;307:1827-37
•Retrospective
study
•APBI
hazard ratio 2.2
(95%CI) vs
mastectomy
•Balloon
technique
Conclusions I• Breast tumours have an a/b=4-4.5 very similar to
late responding tissues. Maybe because the tumour is removed and radiation acts on the residual cells.
• Hypofractionation should be more useful, but the therapeutic window is narrow.
• If the selected schedule is overtreating, the complications rate will be unacceptable.
• If it is undertreating, we cannot appreciate it because the cases treated with APBI have a low rate of relapse and the outcome must be evaluated at least at ten years of FU.
Conclusions II
• When the dose per fraction increases moderately, toxicity is similar if the total dose is decreased.
• Accelerated protocols have the same efficacy if the total duration is decreased.
• Doses of HDR APBI schedules are very variable.
• The standard schedules are 3.4Gy x10 or 4Gy x8
• More hypofractionated protocols are under investigation.
• Probably in the future shorter schedules will be recommended.
Thank you for your attention